NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

901.35 7.70 (0.86%)

High volume today

NSE 30 Sep, 2025 3:31 PM (IST)

17,717.2

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

05 May 2021

901.35

0.86%

COVID-led compliance delay at new sites moderates US outlook

Neutral: Alembic Pharmaceuticals Ltd.

Motilal Oswal

Alembic Pharma (ALPM)'s 4QFY21 operational performance was marginally below estimates, largely due to lower traction in US / Domestic Formulation (DF) sales. ALPM awaits feedback from the USFDA on the resolution of observations at the recently inspected injectables Unit (F3). We tweak our estimates for FY22/FY23, factoring in a) a slowdown in US sales and b) lower expensing of operational cost related to newer facilities. We continue to value ALPM at 19x 12M forward earnings to arrive at TP of INR1,070. We maintain Neutral on a limited upside from current levels....

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

05 May 2021

901.35

0.86%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

ICICI Securities Limited

Q4 revenues grew 6.1% YoY to | 1280 crore with strong growth in RoW formulations and API segment being partly offset by 17.7% YoY decline in US sales to | 475 crore. Domestic formulations grew 4.7% YoY to | 358 crore. RoW sales grew a robust 76.5% YoY to | 233 crore whereas API segment grew 38.1% YoY to | 214 crore. EBITDA margins declined 45 bps YoY to 26.7% with lower gross margins being mostly offset by lower...

Alembic Pharmaceuticals Ltd. is trading at high day volume of 296.7K.

Alembic Pharmaceuticals Ltd.

20 Jan 2021

901.35

0.86%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Q3 results were a mixed bag. While operational performance was below Idirect estimates amid lower than expected International (mainly US) and API sales, net profit was higher due to higher-than-expected profit contribution from Rhizen Phama (one-off). Revenues grew 8.7% YoY to | 1314 crore led by strong growth in domestic, ROW formulations and API segment. US sales growth remained muted (down 0.6% YoY) at | 512 crore due to competition in Sartans. Domestic formulations grew 13.6% YoY to | 418 crore. EBITDA margins expanded 89 bps YoY to 27.8% due to better gross margins and lower R&D; cost. Subsequently, EBITDA grew 12.3% YoY to |...

Alembic Pharmaceuticals Ltd. is trading at high day volume of 296.7K.

Alembic Pharmaceuticals Ltd.

19 Jan 2021

901.35

0.86%

US sales moderate on increased competition in some products

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

We lower our PAT estimate by 3%/4% for FY22/FY23, factoring in higher competition for Sartans and delay in approvals for injectable products. We continue to value ALPM at 19x (in line with its five-year average) 12M forward earnings to arrive at TP of INR1,070. Maintain Neutral....

Alembic Pharmaceuticals Ltd. is trading at high day volume of 296.7K.

Alembic Pharmaceuticals Ltd.

19 Jan 2021

901.35

0.86%

Alembic Pharma (BUY): Q3 misses estimates but India beat looks sustainable

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Alembic Pharma (ALPM) reported a 12% EBITDA miss due to weak sales.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

23 Oct 2020

901.35

0.86%

Alembic Pharmaceuticals

Buy: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

23 Oct 2020

901.35

0.86%

Alembic Pharma

Buy: Alembic Pharmaceuticals Ltd.

Target

Yes Securities

Alembic Pharmaceuticals Ltd. is trading at high day volume of 296.7K.

Alembic Pharmaceuticals Ltd.

22 Oct 2020

901.35

0.86%

Alembic Pharma (BUY): Good beat (ex-US) fuels earnings upgrade

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Alembic Pharma (ALPM) reported a 12% EBITDA beat, with strong growth in ROW, API and India while US sales were in line.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

23 Jul 2020

901.35

0.86%

Alembic Pharmaceuticals

Buy: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Domestic sales comprise 31% of FY20 revenues with higher contribution from specialty (54% of domestic sales). However, despite having an established set-up, growth (FY16-20 CAGR of ~5%) has lagged the industry growth curve. Alembic is consciously focusing on this aspect by overhauling distribution channels (defocusing on trade generics). Overall, we expect...

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

23 Jul 2020

901.35

0.86%

Alembic Pharmaceuticals Ltd

Sell: Alembic Pharmaceuticals Ltd.

Target

Karvy

Valuation and Risks: We upgrade our revenues by 3.2% / 3.3% for FY21E/FY22E at Rs 52 bn / Rs 56 bn respectively due to upgrade in US, ROW and API business.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf